These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39197428)

  • 1. The Short-Term Efficacy and Safety of Faricimab in Refractory Neovascular Age-Related Macular Degeneration: The Real-World Experience in Taiwan.
    Chi SC; Weng CC; Chen SJ; Lin TC; Chou YB; Hwang DK
    Ophthalmologica; 2024; 247(5-6):312-321. PubMed ID: 39197428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Meta-Analysis.
    Nichani PAH; Popovic MM; Mihalache A; Pathak A; Muni RH; Wong DTW; Kertes PJ
    Ophthalmologica; 2024; 247(5-6):355-372. PubMed ID: 39362194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population.
    Fukuda Y; Notomi S; Shiose S; Maehara Y; Kiyohara K; Fujiwara K; Hashimoto S; Kano K; Ishikawa K; Hisatomi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2024 Dec; 262(12):3971-3978. PubMed ID: 39073562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
    Agostini H; Abreu F; Baumal CR; Chang DS; G Csaky K; Demetriades AM; Kodjikian L; Lim JI; Margaron P; Monés JM; Peto T; Ricci F; Rüth M; Singh RP; Stoilov I; Swaminathan B; Willis JR; Westenskow PD
    Graefes Arch Clin Exp Ophthalmol; 2024 Nov; 262(11):3437-3451. PubMed ID: 38847896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India - Multicentric, real-world study.
    Singh DV; Agarwal A; Goyal A; Shroff D; Singh J; Kumar P; Reddy RR; Venkatesh R; Narnaware S; Joshi S; Singh DV; Narula R; Joshi A; Agarwal A; Goyal A; Gupta C; Shroff D; Anantharaman G; Singh J; Kumar P; Bawankule P; Reddy RR; Jain R; Venkatesh R; Tiwari R; Sugumar S; Gupta SR; Narnaware S; Joshi S; Choudhary SP;
    Indian J Ophthalmol; 2024 Dec; 72(12):1786-1794. PubMed ID: 39620667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supplemental Intravitreal Ranibizumab Injections in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial.
    Nielsen JS; Chang A; Holekamp NM; Cavichini-Cordeiro M; Lin SL; Heinrich D; Maass KF; Menezes A; Singh N; Pieramici DJ
    Ophthalmol Retina; 2024 Dec; 8(12):1127-1139. PubMed ID: 38914294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema.
    Maguire M; Laidlaw D; Davies N; Hammond C
    Graefes Arch Clin Exp Ophthalmol; 2024 Nov; 262(11):3501-3508. PubMed ID: 38771336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting long-term functional anti-VEGF treatment outcomes in neovascular AMD in a real-world setting.
    Pfister IB; Schild C; Garweg JG
    PLoS One; 2024; 19(11):e0314167. PubMed ID: 39585864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on corneal endothelium of intravitreal injection of anti-VEGF drugs.
    Malvasi M; Calandri A; Pacella E; Vingolo EM
    Cutan Ocul Toxicol; 2024 Dec; 43(4):369-382. PubMed ID: 39560148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Efficacy and Safety of Aflibercept Biosimilar (P041) Compared with Originator Product in Patients with Neovascular Age-Related Macular Degeneration.
    Karkhaneh R; Faghihi H; Riazi-Esfahani H; Abrishami M; Bazvand F; Ebrahimiadib N; Johari M; Akhlaghi M; Shoeibi N; Nowroozzadeh MH; Ansari Astaneh MR; Khojasteh H; Imani Fooladi M; Khodabande A; Ghassemi F; Khalili Pour E; Zarei M; Mirshahi A; Fazel F; Ashraf H; Hosseini SM; Dourandeesh M; Feghhi M; Alizadeh Y; Behboudi H; Azadi P; Sabzvari A; Kafi H; Ghasemi Falavarjani K
    Ophthalmol Retina; 2024 Aug; 8(8):744-753. PubMed ID: 38428459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year outcomes of intravitreal brolucizumab for neovascular age-related macular degeneration: treat, extend, and stop-protocol.
    Yoshida H; Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Takahashi H; Kawashima H; Yanagi Y
    Graefes Arch Clin Exp Ophthalmol; 2024 Dec; 262(12):3815-3823. PubMed ID: 38995352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights Into Cataract Surgery Outcomes In Age-Related Macular Degeneration: Real-World Perspectives Across Severity Grades.
    Ho Ssl L; Vaghefi SA; Riemer T; Kabiri P; Bonaventura T; Ru Bsam A; Joussen AM; Zeitz O
    Ophthalmol Retina; 2024 Nov; ():. PubMed ID: 39615671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema.
    Diack C; Avery RL; Cheung CMG; Csaky KG; Gibiansky L; Jaminion F; Gibiansky E; Sickert D; Stoilov I; Cosson V; Bogman K
    Transl Vis Sci Technol; 2024 Nov; 13(11):13. PubMed ID: 39535745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumatic displacement of submacular haemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Sim SS; Cheong KX; Chan HH; Choo JQH; Tsai ASH; Lee SY; Yeo IYS; Cheung CMG; Teo KYC
    Eye (Lond); 2024 Dec; 38(17):3374-3381. PubMed ID: 39294233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Multimodal Imaging Characterization of Intraretinal Cysts versus Degenerative Pseudocysts in Neovascular Age-Related Macular Degeneration.
    Arrigo A; Aragona E; Battaglia Parodi M; Bandello F
    Ophthalmol Retina; 2024 Dec; 8(12):1118-1126. PubMed ID: 38848872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of choroidal structure changes after intravitreal anti-VEGF therapy for retinal vein occlusion.
    Dursun E; Derhem B; Çobanoğlu S; Oğurel T
    Graefes Arch Clin Exp Ophthalmol; 2024 Dec; 262(12):3837-3845. PubMed ID: 39037469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.
    Dervenis P; Dervenis N; Smith JM; Steel DH
    Cochrane Database Syst Rev; 2023 May; 5(5):CD008214. PubMed ID: 37260074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Are the Functional, Radiographic, and Survivorship Outcomes of a Modified Cup-cage Technique for Pelvic Discontinuity?
    Mu W; Xu B; Wahafu T; Wang F; Guo W; Zou C; Cao L
    Clin Orthop Relat Res; 2024 Dec; 482(12):2149-2160. PubMed ID: 38991223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BNT162b2 vaccine booster dose did not influence the activity of the exudative form of age-related macular degeneration during anti-vascular endothelial growth factor therapy.
    Płatkowska-Adamska B; Bociek A; Kal M; Zarębska-Michaluk D; Odrobina D
    Minerva Med; 2024 Dec; 115(6):643-650. PubMed ID: 39392292
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.